Early research (Phase 1)Study completedNCT01317875
What this trial is testing
Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)
Who this might be right for
Myelofibrosis
Incyte Corporation 69